MRI screening may identify high-risk pancreatic cancer
the ONA take:
MRI-based screening may be effective in identifying high-risk pancreatic cancer, according to a recent study published in JAMA Surgery.
Researchers led by Marco Del Chiaro, MD, PhD, of the Karolinska Institute in Stockholm looked at 40 patients (24 women, 16 men) who were at genetic risk of developing pancreatic cancer in order to determine short-term results of a MRI-based screening program.
Median follow-up was 12.9 months, and MRI screening was repeated after one year if initial screening was negative or at six months if findings were unspecific.
The researchers were able to find pancreatic lesions in 16 patients – 40 percent – with 14 who had intraductal papillary mucinous neoplasia and two who had pancreatic ductal adenocarcinoma.
“An MRI-based protocol for the surveillance of individuals at risk for developing pancreatic cancer seems to detect cancer or premalignant lesions with good accuracy,” the authors concluded. “The exclusive use of MRI can reduce costs, increase availability and guarantee the safety of the individuals under surveillance compared with protocols that are based on more aggressive methods.”
However, the authors emphasize that their study did not allow for evaluation of efficacy as single-screening modality, due to the small patient sample.
MRI-based screening may be effective in identifying high-risk pancreatic cancer.
Sign Up for Free e-newsletters
- A Witness to Letting Go: Nursing Care at the End of Life
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Risk for Cardiovascular Disease Higher in Survivors of Testicular Cancer
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- Age Not a Deterrent to Immunotherapy for Malignant Melanoma
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Patients With Head and Neck Cancer Have Greater Chance of Being Prescribed Opioids
- Medical Terms in Patient Education: Using the Confusing to Explain the Complicated
- Bedside Assessment Tool Improves Worst Pain in Patients With Cancer
- Androgen-Deprivation Therapy for Prostate Cancer May Cause Nocturia, Sleep Disturbance
- USPSTF Rates Ovarian Cancer Screening a D for Asymptomatic, Low-Risk Women
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|